2020
Racial and socioeconomic disparities differentially affect overall and cause-specific survival in glioblastoma
Liu E, Yu S, Sulman E, Kurz S. Racial and socioeconomic disparities differentially affect overall and cause-specific survival in glioblastoma. Journal Of Neuro-Oncology 2020, 149: 55-64. PMID: 32617722, DOI: 10.1007/s11060-020-03572-y.Peer-Reviewed Original ResearchConceptsCause-specific mortalityMedian household incomeNational Cancer Institute's SurveillanceHousehold incomeCalendar year of diagnosisAssociated with all-cause mortalityNon-Hispanic whitesMethodsThe National Cancer Institute’s SurveillanceAll-cause mortalityCox proportional hazards modelsYear of diagnosisSocioeconomic disparitiesProportional hazards modelAsian/Pacific IslanderInstitute's SurveillanceHispanic whitesSocioeconomic groupsTreatment receiptPatient raceNon-glioblastomaCohort dataSocioeconomic factorsCause-specific mannerInclusion criteriaBlack race
2018
PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma.
Kurz S, Cabrera L, Hastie D, Huang R, Unadkat P, Rinne M, Nayak L, Lee E, Reardon D, Wen P. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology 2018, 91: e1355-e1359. PMID: 30171077, DOI: 10.1212/wnl.0000000000006283.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumabBrain NeoplasmsFemaleGliomaHumansMaleMiddle AgedNeoplasm Recurrence, LocalNivolumabProgrammed Cell Death 1 ReceptorRetrospective StudiesSalvage TherapySurvival AnalysisTreatment OutcomeYoung AdultConceptsRecurrent high-grade gliomaHigh-grade gliomasRetrospective observational studySalvage therapySurvival benefitSingle-institution retrospective observational studyPD-1 blocking antibodiesObservational studyPD-1 inhibitionProgression-free survivalClass IV evidenceConcurrent bevacizumabAntibody nivolumabPD-1Median survivalClinical benefitImproved survivalNivolumabPembrolizumabAdult patientsBevacizumabIV evidenceClinical trialsPatient populationPatients